RxDoctor Payments Data

Kyli Myears

Nurse Practitioner · Branson, MONPI 1881032795

Payments from drug & device makers

$3,775in general payments, 2019–2025

Across 140 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$756
  • Inspire Medical Systems, Inc.$302
  • Medtronic$287
  • Regeneron Healthcare Solutions, Inc.$267
  • Novartis$229
  • Abbott$214
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,69598%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,775 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$43,243
Medicare patients
525
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$194,542
EntrestoSacubitril/Valsartan131$129,950
JardianceEmpagliflozin129$115,482
XareltoRivaroxaban59$51,488
FarxigaDapagliflozin Propanediol14$17,023
Praluent PenAlirocumab11$6,963
Propafenone Hcl16$2,603
Flecainide Acetate62$2,285
Metoprolol Succinate252$2,117
Midodrine Hcl18$1,803
Isosorbide Mononitrate ErIsosorbide Mononitrate147$1,102
Ezetimibe69$818
Bumetanide47$747
Atorvastatin Calcium115$741
Amiodarone Hcl57$684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$194,542260 claims
NovartisEntresto$229$129,950131 claims
Boehringer IngelheimJardiance$153$115,482129 claims
Johnson & JohnsonXarelto$77$51,48859 claims
AstraZenecaFarxiga$756$17,02314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Branson

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →